

CIN: L29110MH1995PLC085738

Regd. Off.: 2<sup>nd</sup> Floor, Pushpawati Building No. 2, Girgaon Road, Chandanwadi, Mumbai –02 Corp. Off.: "Suryarath", 1<sup>st</sup> Floor, Panchwati, 1<sup>st</sup> Lane, Ambawadi, Ahmedabad – 06 Phone: +91-6359637788, Email: investor.relations@jindalonline.com,

Website: www.kashyaptele-medicines.com

Date: 3rd June, 2019

To,
BSE Limited
Listing Department,
Phiroz Jeejeebhoy Tower,
25<sup>th</sup> Floor, Dalal Street,
Mumbai-400 001

Scrip Code - 531960

Ref.: Our letter of Outcome of Board Meeting held on 20th May, 2019

Sub.: Revised Outcome of Board Meeting held on 20th May, 2019

Dear Sir/Madam,

With reference to the above, kindly find attached herewith the revised outcome of Board Meeting held on 20<sup>th</sup> May, 2019 and ignore the previous one as submitted on 20<sup>th</sup> May, 2019, due to some inadvertent typographical error.

We regret the inconvenience caused.

You are requested to take the same on record and oblige the same.

Thanking you.

Yours faithfully,

FOR, KASHYAP TELE-MEDICINES LIMITED

PRERNA KAKKAR

COMPANY SECRETARY

Encl: As above



CIN: L29110MH1995PLC085738

Regd. Off.: 2<sup>nd</sup> Floor, Pushpawati Building No. 2, Girgaon Road, Chandanwadi, Mumbai –02 Corp. Off.: "Suryarath", 1<sup>st</sup> Floor, Panchwati, 1<sup>st</sup> Lane, Ambawadi, Ahmedabad – 06 Phone: +91-6359637788, Email: <a href="mailto:investor.relations@jindalonline.com">investor.relations@jindalonline.com</a>,

Website: www.kashyaptele-medicines.com

Date: 20th May, 2019

To,
BSE Limited
Listing Department,
Phiroz Jeejeebhoy Tower,
25<sup>th</sup> Floor, Dalal Street,
Mumbai-400 001

Scrip Code - 531960

Sub.: Outcome of Board Meeting held on 20<sup>th</sup> May, 2019 as per Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Dear Sir/Madam,

With reference to above and as per intimation given for meeting of the Board of Directors, we are pleased to inform that above referred meeting was held on 20<sup>th</sup> May, 2019 and Board of Directors has considered and approved, inter alia:

- 1. Audited Financial Results of the Company for the quarter *I* year ended 31<sup>st</sup> March, 2019 as per Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Further note that the Statutory Auditor of the Company have issued audit report with unmodified opinion in this regards;
- Appointment of Mr. Raghav Agrawal (DIN: 02264149) as an Additional Director Non Executive Non Independent Director of the Company w.e.f. 21<sup>st</sup> May, 2019, to be further regularize as a Director subject to the approval of the Members at the ensuing Annual General Meeting of the Company. Brief profile of Mr. Raghav Agrawal is enclosed;
- 3. Appointment of Mr. Mayank Khetan (DIN: 02412971) as an Additional Director Independent Director of the Company for the term of 5 (five) years w.e.f. 21<sup>st</sup> May, 2019 upto 20<sup>th</sup> May, 2024, to be further regularize as a Director subject to the approval of the Members at the ensuing Annual General Meeting of the Company. Brief profile of Mr. Mayank Khetan is enclosed;

Further, None of the aforementioned Directors has been debarred from holding the office of Director by virtue of any order passed by SEBI or any such authority.

4. Resignation of Mr. Girwarsingh Shekhawat (DIN: 06940371), as a Non Executive Independent Director of the Company, vide his resignation letter dated 11<sup>th</sup> May, 2019, due to personal and unavoidable circumstances w.e.f. 21<sup>st</sup> May, 2019. Further, Mr. Girwarsingh Shekhawat has confirmed that there is no other material reason for his resignation as Director of the Company, other than those cited above.



CIN: L29110MH1995PLC085738

Regd. Off.: 2<sup>nd</sup> Floor, Pushpawati Building No. 2, Girgaon Road, Chandanwadi, Mumbai –02 Corp. Off.: "Suryarath", 1<sup>st</sup> Floor, Panchwati, 1<sup>st</sup> Lane, Ambawadi, Ahmedabad – 06 Phone: +91-6359637788, Email: investor.relations@jindalonline.com,

Website: www.kashyaptele-medicines.com

- Resignation of Mr. Dinesh Ghewar Chand Jain (DIN: 00216803), as a Non Executive Non Independent Director of the Company, vide his resignation letter dated 11<sup>th</sup> May, 2019, due to personal preoccupations w.e.f. 21<sup>st</sup> May, 2019.
- 6. all other businesses as per agenda circulated.

The Meeting of the Board of Directors commenced at 2.00 p.m. and concluded at 3.30 p.m.

Kindly take the above disclosures on your record as compliance with Regulations 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

You are requested to take note of the same.

Thanking you.

Yours faithfully,

FOR, KASHYAP TELE-MEDICINES LIMITED

PRERNA KAKKAR

COMPANY SECRETARY

Encl: As above



CIN: L29110MH1995PLC085738

Regd. Off.: 2<sup>nd</sup> Floor, Pushpawati Building No. 2, Girgaon Road, Chandanwadi, Mumbai –02 Corp. Off.: "Suryarath", 1<sup>st</sup> Floor, Panchwati, 1<sup>st</sup> Lane, Ambawadi, Ahmedabad – 06 Phone: +91-6359637788, Email: investor.relations@jindalonline.com,

Website: www.kashyaptele-medicines.com

# Disclosure required pursuant to Regulation 30(2) & Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Contents of Disclosures	Details of information				
	Mr. Mayak Khetan (DIN 02412971)	Mr. Raghav Agrawal (DIN 02264149)			
Reason for Change viz appointment	Due to resignation of Mr. Girwarsingh Shekhawat as a Non Executive Independent Director of the Company, it has become necessary to appoint an Independent Director in order to comply up with the provision of the Companies Act, 2013 and SEBI (LODR) Regulations, 2015. Thus, on the Recommendation of the Nomination and Remuneration Committee, the Board of Directors has approved the appointment of Mr. Mayank Khetan (DIN 02412971) as an Additional Director - Independent Director of the Company.	Due to resignation of Mr. Dinesh Ghewar Chand Jain, as a Non Executive Non Independent Director of the Company, it has become necessary to appoint a Non Executive Non Independent Director in order to comply up with the provision of the Companies Act, 2013 and SEBI (LODR) Regulations, 2015. Thus, on the Recommendation of the Nomination and Remuneration Committee, the Board of Directors has approved the appointment of Mr. Raghav Agrawal (DIN 02264149) as an Additional Director - Non Executive Non Independent Director of the Company.			
Terms of appointment	For the term of 5 (five) years w.e.f. 21 <sup>st</sup> May, 2019 upto 20 <sup>th</sup> May, 2024, subject to the approval of members in the ensuing Annual General Meeting, on the Terms and Conditions as may be decided by the Board of Directors and Mr. Mayank Khetan from time to time.	Appointment w.e.f. 21 <sup>st</sup> May, 2019, subject to the approval of members in the ensuing Annual General Meeting, on the Terms and Conditions as may be decided by the Board of Directors and Mr. Raghav Agrawal from time to time.			
Brief Profile	Mr. Mayank Khetan, aged 32 years, is a Graduate in Science and MBA from Kanpur University. He is having 10 years of rich experience in Textiles Sector. He is a visionary and an entrepreneur and handling textile business from a very young age. He has extensive experience and expertise in the fields of the Textile Business, Business Strategy, Sales and Marketing.	Mr. Raghav Agrawal, aged 31 years, is a Graduate in Business Administration in Economic from Michigan State University, USA. He has distinguished academic career and an extensive administrative, economic and managerial expertise with his vast experience of over 9 years in creation of new services, products and strategies, which will enable the Company to decide future business strategies for its growth and development. He is an expert in Project Execution, Strategic Planning, Leadership Development, Customer Engagement and Risk Mitigation.			
Relationship with Directors	Mr. Mayank Khetan is not related to any of the existing Directors of the Company.	Mr. Raghav Agrawal is not related to any of the existing Mirgorns of the Company.			



# SAREMAL & CO

### Chartered Accountants

CA Saremal shah (Bcom, FCA); CA Pravin Lavana (Bcom, LLB, FCA)

Auditor's Report on the Quarterly Financial Results and Year to Date Results of M/s. Kashyap Tele-Medicines Limited pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To
The Board of Directors,
KASHYAP TELE-MEDICINES LIMITED

- We have audited the Financial Results of the Company "M/s. KASHYAP TELE-MEDICINES LIMITED" (the 'Company'), for the quarter and financial year ended on 31<sup>st</sup> March, 2019, attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligation and Disclosure requirements) Regulations, 2015 read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated 05<sup>th</sup> July, 2016.
- 2. The said Financial Results of the Company for the quarter and financial year ended on 31<sup>st</sup> March, 2019, which is the responsibility of the Company's Management and approved by the Board of Directors, has been compiled from the respective Annual Financial Statements which have been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standards (IND-AS 34) prescribed under Section 133 of the Companies Act, 2013, read with the Companies (Indian Accounting Standards) Rules, 2015 issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express an opinion on these financial results based on our audit of such Annual Financial Statements and thus we state that our opinion as unmodified in respect of same.
- 3. We conducted our audit in accordance with the Auditing Standards generally accepted in India. Those Standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial results are free of material misstatement. An audit includes examining, on test basis, evidence supporting the amounts disclosed in financial results. An audit also includes assessing the accounting principles used and the significant estimates made by the Management. We believe that our audit provides a reasonable basis for our opinion.
- 4. In our opinion and to the best of our information and according to the explanations given to us, the said Financial Results of the Company for the quarter and financial year ended on 31<sup>st</sup> March, 2019:
  - (i) are presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI circulars no. CIR/CFD/FAC/62/2016 dated 05<sup>th</sup> July, 2016; and
  - (ii) give a true and fair view of the Net Profit and other financial information of the Company.

5. The figures for the Quarter ended 31<sup>st</sup> March, 2019 being the balancing figure between audited figures in respect of the full financial year ended on 31<sup>st</sup> March, 2019 and the published year to date figures up to the third quarter of the current financial year i.e. 31<sup>st</sup> December, 2018, which were subject to limited review by us. Our audit report is not modified in respect of this matter.

Place : Ahmedabad

Date: 20th May, 2019

FOR, SAREMAL & CO.
CHARTERED ACCOUNTANTS

PRAVIN LAVANA (PARTNER)

MEMBERSHIP NO.: 037180

FIRM REGISTRATION NO.: 109281W -

CIN: L29110MH1995PLC085738

Regd. Off.: 2nd Floor, Pushpawati Building No. 2, Girgaon Road, Chandanwadi, Mumbai -02 Corp. Off.: "Suryarath", 1st Floor, Panchwati, 1st Lane, Ambawadi, Ahmedabad - 06

Phone: +91-6359637788, Email: investor.relations@jindalonline.com Website: www.kashyaptele-medicines.com

						s Except EPS
S.No.	Particulars	Quarter Ended (Standalone)			Year Ended	
		31/03/2019	31/12/2018	31/03/2018	31/03/2019	31/03/2018
		(Audited)	(Unaudited)	(Audited)	(Audited)	(Audited)
1	Revenue from operations	5.90	4.65	4.65	19.85	18.00
11	Other Income	0.00	0.00	0.07	0.00	0.11
III	Total Revenue (1+II )	5.90	4.65	4.72	19.85	18.11
IV	Expenses					
	(a) Cost of materials consumed	0.00	0.00	0.00	0.00	0.00
	(b) Purchases of stock-in-trade	0.00	0.00	0.00	0.00	0.00
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	0.00	0.00	0.00	0.00	0.00
-	(d) Employee benefits expense	3.97	2.18	1.62	9.93	6.27
	(e) Finance Cost	0.00	0.00	0.00	0.00	0.00
	(f) Depreciation and amortisation expense	0.00	0.00	0.00	0.00	0.00
	(g) Other expenses	1.87	1.42	1.83	6.83	6.91
	Total expenses	5.84	3.60	3.45	16.76	13.18
٧	Profit/(Loss) before exceptional and extraordinary items and tax (III-IV)	0.06	1.05	1.27	3.09	4.93
VI	Exceptional Items	0.00	0.00	0.00	0.00	0.00
VII	Profit before Extraordinary Items and tax (V - VI )	0.06	1.05	1.27	3.09	4.93
VIII	Extraordinary items	0.00	0.00	0.00	0.00	0.00
IX	Profit/(Loss) Before Tax ( VII- VIII)	0.06	1.05	1.27	3.09	4.93
X	Tax Expense :-					
	(a) Current tax	0.01	0.28	0.00	0.78	0.94
	(b) Deferred tax	0.00	0.00	0.00	0.00	0.00
XI	Profit / (Loss) for the period from Continuing Operations (IX - X)	0.05	0.77	1.27	2.31	3.99
XII	Profit/(loss) from Discontinuing Operations	0.00	0.00	0.00	0.00	0.00
XIII	Tax Expense of Discontinuing Operations	0.00	0.00	0.00	0.00	0.00
XIV	Profit/(loss) from Discontinuing operations (after tax) (XII-XIII)	0.00	0.00	0.00	0.00	0.00
XV	Profit / (Loss) for the period (XI + XIV )	0.05	0.77	1.27	2.31	3.99
XVI	Share of profit / (loss) of Associates*	0.00	0.00	0.00	0.00	0.00
XVII	Minority interest	0.00	0.00	0.00	0.00	0.00
XVIII	Profit / (Loss) after taxes, minority interest and share of profit / (loss) of associates*	0.05	0.77	1.27	2.31	3.99
XIX	Other Comprehensive Income					
	A. Items that will be/will not be reclassified to profit and loss	0.00	0.00	0.00	0.00	0.00
	B. Income tax relating to items that will be / will not be reclassified to profit and loss	0.00	0.00	0.00	0.00	0.00
	Total comprehensive income for the period (XVIII+XIX)	0.05	0.77	1.27	2.31	3.99
XX	Paid-up Equity Share Capital (Face Value of Rs. 1/- each)	477.22	477.22	477.22	477.22	477.22
XXI	Reserve excluding Revaluation Reserves as per balance sheet of previous accounting year				(240.22)	(242.53
XXII	Earnings per equity share:					

#### Notes:

(a) Basic

(b) Diluted

The above Audited Financial Results of the Company for the quarter and year ended on 31st March, 2019 have been reviewed by the Audit Committee and approved by the Board of Directors in the Meeting held on 20th May, 2019. The Statutory Auditors have expressed an unmodified audit opinion with respect to the Audited Financial Results of the Company for the quarter and year ended on 31st March, 2019.

0.000

0.000

0.002

0.002

0.003

0.003

0.005

0.005

0.008

0.008

- The Company has adopted, Indian Accounting Standards prescribed under Section 133 of the Companies Act, 2013 ('Ind As') from 1st April, 2017 and accordingly these financial results and all the periods presented have been prepared in accordance with the recognition and measurement principles laid down in Ind AS 34 "Interim Financial Reporting" read with relevant rules issued thereunder and the other accounting principles generally accepted in India and discloses the information required to be disclosed in terms of Regulation 33 of the SEBI ( Listing Obligations and Disclosure Requirements) Regulation, 2015 (as amended).
- A Copy of the aforesaid financial results is also available on the website of BSE Limited (www.bseindia.com) and on the website of the Company (www.kashyaptele-medicines.com).
- encoded in single segment therefore has only one reportable segment in accordance with Ind AS 108 'operating segments'.

Figure periods have been re-grouped and re-arranged wherever necessary.

Place : Ahmedab Date : 20th May, 2019

0

For, Kashyap Tele - Medicines Limited

Managing Director

Amit Agrawal DIN: 00169061 -Med

CIN: L29110MH1995PLC085738

Regd. Off.: 2nd Floor, Pushpawati Building No. 2, Girgaon Road, Chandanwadi, Mumbai –02 Corp. Off.: "Suryarath", 1st Floor, Panchwati, 1st Lane, Ambawadi, Ahmedabad – 06 Phone: +91-6359637788, Email: investor.relations@jindalonline.com

Website: www.kashyaptele-medicines.com

#### STANDALONE AUDITED BALANCE SHEET AS AT 31st MARCH, 2019

Rs. In Lakhs

		As at 31.03.2019 (Audited)	As at 31.03.2018 (Audited)
ASSETS		(Addited)	(Addited)
	Current Assets		
	Property, Plant and Equipment		
	Capital work in progress		
(c)	Financial Assets		
	(i) Investments	21	2
	(ii) Other Financial Assets	0.34	0.3
(d)	Other Non-Current Assets	191.69 213.03	191.6 213.0
II Curre	nt Assets	223.03	225.0
(a)	Inventories		
	Financial Assets		
1-7	(i) Trade Receivables	12.40	12.2
	(ii) Cash and Cash Equivalents	14.62	11.4
	(iii) Investments		
	(iv) Loans		0.1
(c)	Other Current Assets	0.75	0.2
19900	Accrued Interest - FDR		
(4)	Actived interest - For	27.77	24.0
	TOTAL ASSETS	240.80	237.0
	Share Capital Other Equity	477.22 (240.23)	477.2 (242.5
		236.99	234.6
	Current Liabilities		
	Long term borrowings		
7	Deferred tax liabilities (net)		
(c)	Other long term liabilities	•	
III Curre	ent Liabilities		
	Financial liabilities		
(0)	(i) Short term borrowings		
	(ii) Trade Payables		
	Total Outstanding dues of micro enterprises and small		
	enterprises		
	Total Outstading dues of creditors other than micro	0.30	0.8
	enterprises and small enterprises	0.50	0.0
	(iii) Other Financial liabilites		
(b)	Other Current Liabilities	2.70	0.5
1,500	Short-Term Provisions		
75.00	Income tax liabilities	0.80	0.9
,-,		3.80	2.3
	TOTAL FOLLOW AND LIABILITIES	240.00	227.0
	TOTAL EQUITY AND LIABILITIES	240.80	237.0
	OFMA.		

Place: Ahmedabac Date: 20th May, 2019

For, Kashyap Tele - Medicines Limited

Amit Agrawal Managing Director DIN: 00169061

Accounta



CIN: L29110MH1995PLC085738

Regd. Off.: 2<sup>nd</sup> Floor, Pushpawati Building No. 2, Girgaon Road, Chandanwadi, Mumbai –02 Corp. Off.: "Suryarath", 1<sup>st</sup> Floor, Panchwati, 1<sup>st</sup> Lane, Ambawadi, Ahmedabad – 06 Phone: +91-6359637788, Email: investor.relations@jindalonline.com,

Website: www.kashyaptele-medicines.com

Date: 20th May, 2019

To, BSE Limited Listing Department, Phiroz Jeejeebhoy Tower, 25<sup>th</sup> Floor, Dalal Street, Mumbai-400 001

Scrip Code - 531960

Sub.: Submission of Declaration Pursuant to Regulation 33(3)(d) of SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015 in respect of Audit Report with Unmodified Opinion for the Annual Audited Financial Results for the Financial Year ended on 31<sup>st</sup> March, 2019

Dear Sir/Ma'am,

With references to the above, the Company do hereby declares that the Statutory Auditors of the Company M/s. Saremal & Co., Chartered Accountants (FRN: 109281W), Ahmedabad have expressed an Unmodified Opinion for their Independent Auditor's Report on Audited Financial Results for the Financial Year ended on 31<sup>st</sup> March, 2019; which are duly considered and approved by the Board of Directors on 20<sup>th</sup> May, 2019 itself.

You are kindly requested to acknowledge and take the above into your records.

Thanking you.

Yours faithfully,

FOR, KASHYAP TELE-MEDICINES LIMITED

AMIT AGRAWAL

MANAGING DIRECTOR

DIN: 00169061